More DD part 2 from today's PR:
Positron has a number of patents and patents pending. Most recently has received a patent on its Tech-Assist™, FDG injection shielding device.
Some POSC current R&D projects"
Positron Corporation Acquires Exclusive License to Coronary Disease Reversal and Prevention Practice Management Program from the University of Texas. HOUSTON Tuesday, 1 July 2008 -- Positron Corporation (OTC: POSC) (the "Company") announced today that it has acquired an exclusive license to a coronary disease reversal and prevention practice management program created by K. Lance Gould, M.D. and the University of Texas Health Science Center at Houston.
"We are grateful to the University of Texas Health Science Center at Houston and Dr. Gould for selecting Positron Corporation as the exclusive licensee of their heart disease management product", stated Joe Oliverio, President of Positron. Oliverio also stated, "the market is void of such a product and will position Positron to be able to offer a total cardiac solution to customers reaching well beyond the sale to physicians."
"The Weatherhead P.E.T. Center of the University of Texas Health Science Center at Houston is unique for having the most advanced myocardial perfusion imaging in the world using positron emission tomography (P.E.T.) integrated with intense lifestyle and pharmacologic treatment proven to reduce invasive procedures and coronary events compared to conventional cardiovascular practices", stated K. Lance Gould, M.D., holder of the Martin Bucksbaum Distinguished University Chair, professor of Cardiovascular Medicine and executive director of the Weatherhead P.E.T. Center for Preventing and Reversing Atherosclerosis, University of Texas Medical School at Houston.
Dr. Gould went on to also state, "This first program for the optimal one-stop combination of diagnostic assessment, vigorous pharmacologic and lifestyle management is PET technology driven but incorporates the humanity and knowledge of the best preventive and clinical medicine. It identifies the earliest stages of coronary disease and before symptoms develop. It also determines when invasive procedures are unnecessary or needed for the most advanced complex coronary heart disease."
"Positron Corporation has recognized the power of this approach for improving cardiovascular care. The University of Texas Health Science Center at Houston- Positron agreement highlights the commitment of the University and Positron for translating the highest quality cardiovascular medicine and research of a renowned academic center into widespread application of community practice."
As part of the program Positron Corporation and Disease Management, LLC has a Signed Agreement to Co-Develop a Coronary Artery Disease Reversal and Prevention Software Program and Total Disease Management Solution.
The product will include a heart disease pre-test risk calculator, a Coronary Disease Reversal and Prevention practice management program, a web-based, patient centric, disease reversal and life style modification program, an interpreting and referring physician portal, as well as a cost efficacy and patient outcomes tracker.
Positron Corporation's President Joseph G. Oliverio stated, "The development of our heart disease management solution will help us reach beyond our current molecular imaging targeted business to offer a product to payers, self insured corporations, multi-specialty groups, cardiology cardiology
Medical specialty dealing with heart diseases and disorders. It began with the 1749 publication by Jean Baptiste de Sénac of contemporary knowledge of the heart. Diagnostic methods improved in the 19th century, and in 1905 the electrocardiograph was invented. groups, hospitals and finally direct to the consumer."
Oliverio also adds that "This is an important step in the growth of our business and the impact on the industry that Positron has been positioning for over the past 2 years. The product introduction will address a first-to-market opportunity in the Coronary Disease Reversal and Prevention sector which strengthens Positron's core products that are focused on providing accurate, cost effective imaging and disease management solutions. One of our many goals is to offer even the smallest community hospitals the same level of quality of our most experienced users."
Total POSC Investment to date: $4Mill. 5 year study for completion in Summer 2013.
AI
